ethics papers
Sport, categories and the creative role of ethics.
Caster Semenya, a South African 18-year-old, won the 800-metre track running title at the Berlin World Athletics Championships in 2009. Her gender has been harshly contested, and
IAAF started an investigation, but then decided not to disclose the results of the tests. But could a scientific or medical test really offer uncontroversial answers regarding such questions? In this paper co-authored with Paolo Maugeri, we argue that ethics should guide science and medicine in making such decisions, and in creating categories.
Silvia Camporesi, Paolo Maugeri
Journal of Medical Ethics, forthcoming, 2010
An ethical way to carry on a cultural bloodline?
Is it morally justifiable to choose to have deaf children through genetic implantation diagnosis? Not science fiction, but an established practice in some assisted-reproduction clinics in the US. In this paper I argue that it is not, on the basis of the arguments of the right to an open future and of fairness.
Silvia Camporesi
Cambridge Quarterly Healthcare Ethics, January 2010
Pistorius' case is a snap-shot into the future of sport. Will the “natural”, able-bodied athletes just appear anachronistic in fifty years or so from now? As our concept of what is ‘natural’ depends on what we are used to, and evolves with our society and culture, so does our concept of ‘purity’ of sport, and our concept of how an Olympics athlete should look like.
Silvia Camporesi
Journal of Medical Ethics, September 2008
Ethical considerations
The US Food and Drug Administration (FDA) announced in April 2008 that it will shelve the Helsinki Declaration and, starting in October 2008, it will adopt a new standard for clinical trials called Good Clinical Practice (GCP). Although GPC deals with subject protection (e.g. Informed consent, privacy), it is silent on the issue of placebo as controls in cases where proven therapies exist.
Is the FDA decision troubling at all from an ethical point of view? And if so, why?
Silvia Camporesi
ecancermedicalscience, June 2008
The ethical challenges of research on cytoplasmic hybrid embryos
Following the controversial HFEA decision (September 2007, January 2008) on the permissibility of research on cytoplasmic hybrid embryos (i.e. Human embryos created by somatic cellular nuclear transfer using a non human animal egg as recipient), I developed arguments together with Giovanni Boniolo to support and justify the HFEA decision from an ethical point of view.
Silvia Camporesi and Giovanni Boniolo
Journal of Medical Ethics, November 2008
is the ethical debate catching up with recent scientific advances?
After the publication, in November 2007, of the successful therapeutic cloning (somatic cellular nuclear transfer) and establishment of embryonic stem cells in primates, I worked with Lisa BortolottiLisa Bortolotti at elaborating arguments in support of therapeutic cloning in humans, aimed at the production of tailore hES cell lines. Here we also analyse the objections to human reproductive cloning and fail to see them as conclusive.
Silvia Camporesi and Lisa Bortolotti
Journal of Medical Ethics, September 2008
Research on human stem cells and embryos creates ethical issues
Research on human stem cells and embryos creates ethical issues. Here I discuss ten frequently used arguments against research and point out their weaknesses. These arguments include the possessed potentiality of the embryo per se and, in contrast to other cell systems, the "slippery slope" argument, the right of disposal of parents, totipotency versus pluripotency, the burden of proof for research, natural versus artificial, and three arguments based on the precaution principle (the open biological questions, uncertainty regarding clinically applicable therapies, and the problem solving rule). I finally suggest a different answer to the ethical questions concerning research on human embryos and embryonic stem cells, which takes into consideration their biological context.
Silvia Camporesi
Biotechnol Journal, September 2007
science communication papers
Conference report on the Phase 0 workshop at the 20th EORT-NCI-AARC symposium on Molecular Targets and Cancer Therapeutics (Geneva, 21-24 October 2008).
Silvia Camporesi
ecancermedicalscience, November 2008
chimera.jpg bardotto.jpg asino.jpg
British authorities’ decision to allow research on “cytoplasmic hybrid embryos” left most people confused
Silvia Camporesi
ONCampus, October-December 2007
In a branch of research crucial for molecular oncology, a comparison between the two Catholic countries in Europe
Silvia Camporesi
ONCampus, July-September 2007; pp67